Get a Quote

AVAPRITINIB
CAS NO.: 1703793-34-3
Chemical Formula: C26H27FN10
Molecular Weight: 498.6000
DMF&GMP status: Please contact us for more details.
Description:
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors. It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
AVAPRITINIBTABLET;ORAL100MGAYVAKITBLUEPRINT MEDICINES CORP
AVAPRITINIBTABLET;ORAL200MGAYVAKITBLUEPRINT MEDICINES CORP
AVAPRITINIBTABLET;ORAL300MGAYVAKITBLUEPRINT MEDICINES CORP
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
920000210/15/2034DSDPU-2726
994465110/15/2034DSDPU-2726
999457510/15/2034DSDPU-2726
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 01/09/2025